Skip to main content
Top

2006 | OriginalPaper | Hoofdstuk

Mogen vrouwen na een mammacarcinoom bij climacteriële klachten tibolon gebruiken?

Auteur : dr. L.V.A.M. Beex

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Oestrogenen en progesteron in doseringen zoals toegepast bij hormonale substitutiebehandeling bij postmenopauzale vrouwen, zijn stimulerende hormonen voor de borstklier en voor hormoonafhankelijk mammacarcinoom. Adjuvante en palliatieve endocriene behandeling van mammacarcinoom beoogt vooral vermindering van de beschikbaarheid van deze stimulerende hormonen voor haar receptoren (uitschakeling ovariële functie; aromataseremmers; anti-oestrogenen).
Literatuur
go back to reference Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
go back to reference Olsson H, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387-92. Olsson H, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387-92.
go back to reference Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002; 109: 886-93. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002; 109: 886-93.
go back to reference Roux C, Pelissier C, Fechtenbaum J, et al. Randomised, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporose Int 2002; 13: 241-48. Roux C, Pelissier C, Fechtenbaum J, et al. Randomised, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporose Int 2002; 13: 241-48.
go back to reference Egarter C, Sator M, Berghammer P, Huber J. Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet 1999; 64: 281-86. Egarter C, Sator M, Berghammer P, Huber J. Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet 1999; 64: 281-86.
go back to reference Lippert C, Seeger H, Wallwiener D, Mueck A. Tibolone versus 17 beta-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. Eur J Gynaecol Oncol 2002; 23:127-30. Lippert C, Seeger H, Wallwiener D, Mueck A. Tibolone versus 17 beta-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. Eur J Gynaecol Oncol 2002; 23:127-30.
go back to reference Kloosterboer HJ. Endocrine prevention of breast cancer: any role for tibolone? Eur J Cancer 2002; 38 (suppl 6): S24-25. Kloosterboer HJ. Endocrine prevention of breast cancer: any role for tibolone? Eur J Cancer 2002; 38 (suppl 6): S24-25.
go back to reference Christodoulakos GE, Lambridounaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002; 9: 110-16. Christodoulakos GE, Lambridounaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002; 9: 110-16.
go back to reference Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Int Med 1999; 130: 262-69. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Int Med 1999; 130: 262-69.
go back to reference Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Gynaecol 2002; 186: 717-22. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Gynaecol 2002; 186: 717-22.
go back to reference Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001; 3: 203-8. Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001; 3: 203-8.
go back to reference Morris EP, Wilson PO, Robinson J, Rymer JM. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999; 106: 954-59. Morris EP, Wilson PO, Robinson J, Rymer JM. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999; 106: 954-59.
go back to reference Gooyer M de, Deckers G, Schoonen W, et al. Receptor profiling and endocrine interactions of tibolone. Steroids 2003; 68: 21-30. Gooyer M de, Deckers G, Schoonen W, et al. Receptor profiling and endocrine interactions of tibolone. Steroids 2003; 68: 21-30.
go back to reference Loprinzi Ch, Barton D, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet oncology 2001; 2: 199-204. Loprinzi Ch, Barton D, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet oncology 2001; 2: 199-204.
go back to reference Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. Br Med J (Dutch edition) 2003; 326: 322-26. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. Br Med J (Dutch edition) 2003; 326: 322-26.
Metagegevens
Titel
Mogen vrouwen na een mammacarcinoom bij climacteriële klachten tibolon gebruiken?
Auteur
dr. L.V.A.M. Beex
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_583